1. Home
  2. BLFS

as of 08-07-2026 4:00pm EST

$34.66
+$0.73
+2.15%
Stocks Health Care Medical/Dental Instruments Nasdaq

BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.

Founded: 1987 Country:
United States
United States
Employees: N/A City: BOTHELL
Market Cap: 1.6B IPO Year: 2013
Target Price: $32.00 AVG Volume (30 days): 1.4M
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 0.94 EPS Growth: 77.27
52 Week Low/High: $17.86 - $34.34 Next Earning Date: 05-07-2026
Revenue: $96,214,000 Revenue Growth: 16.97%
Revenue Growth (this year): 19.73% Revenue Growth (next year): 17.82%
P/E Ratio: 1696.50 Index: N/A
Free Cash Flow: 10.6M FCF Growth: +210.94%

AI-Powered BLFS Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 4 days ago

AI Recommendation

hold
Model Accuracy: 73.63%
73.63%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of BioLife Solutions Inc. (BLFS)

BLFS May 21, 2026

Avg Cost/Share

$23.70

Shares

650,000

Total Value

$15,405,000.00

Owned After

4,757,165

SEC Form 4

BLFS May 20, 2026

Avg Cost/Share

$23.70

Shares

250,000

Total Value

$5,925,000.00

Owned After

4,757,165

SEC Form 4

BLFS May 19, 2026

Avg Cost/Share

$22.65

Shares

300,000

Total Value

$6,795,000.00

Owned After

4,757,165

SEC Form 4

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q1

Q1 2026 Earnings

8-K SELL

May 7, 2026 · 100% conf.

AI Prediction SELL

1D

-3.76%

$22.25

Act: -4.50%

5D

-11.64%

$20.43

Act: -8.91%

20D

+0.78%

$23.30

Act: +15.27%

Price: $23.12 Prob +5D: 0% AUC: 1.000
0001628280-26-032123

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1784722692.738b40e

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2025
Q4

Q4 2025 Earnings

8-K BUY

Feb 26, 2026 · 100% conf.

AI Prediction BUY

1D

+9.25%

$24.56

Act: +8.12%

5D

+15.55%

$25.97

Act: -10.50%

20D

+12.42%

$25.27

Price: $22.48 Prob +5D: 100% AUC: 1.000
0001628280-26-012264

blfs-20260226false0000834365Nasdaq00008343652026-02-262026-02-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter)

Delaware001-3636294-3076866 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)

3303 Monte Villa Parkway, Bothell, WA 98021 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (425) 402-1400

N/A (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading symbolName of exchange on which registered Common Stock, par value $0.001 per shareBLFSThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02    Results of Operations and Financial Condition. On February 26, 2026, BioLife Solutions, Inc. ("the Company"), a Delaware corporation, issued a press release announcing financial results and operational highlights for the fourth quarter and year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01    Financial Statements and Exhibits. (d) Exhibits

Exhibit No.Description 99.1Press release, dated February 26, 2026

104Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BioLife Solutions, Inc.

Date: February 26, 2026 By:/s/ Troy Wichterman Name: Troy Wichterman Title: Chief Financial Officer

2025
Q4

Q4 2025 Earnings

8-K BUY

Jan 12, 2026 · 100% conf.

AI Prediction BUY

1D

+9.25%

$24.56

Act: +8.12%

5D

+15.55%

$25.97

Act: -10.50%

20D

+12.42%

$25.27

Price: $22.48 Prob +5D: 100% AUC: 1.000
0001628280-26-001767

blfs-20260112false0000834365Nasdaq00008343652026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter)

Delaware001-3636294-3076866 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)

3303 Monte Villa Parkway, Bothell, WA 98021 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (425) 402-1400 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading symbolName of each exchange on which registered Common Stock, par value $0.001 per shareBLFSThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02    Results of Operations and Financial Condition.

On January 12, 2026, the BioLife Solutions, Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenue for the fourth quarter and year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01    Financial Statements and Exhibits. (d) Exhibits

Exhibit No.Description 99.1Press Release of BioLife Solutions, Inc., dated January 12, 2026.

104Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BioLife Solutions, Inc.

Date: January 12, 2026 By:/s/ Troy Wichterman Name: Troy Wichterman Title: Chief Financial Officer

Share on Social Networks: